Ren Xinwen, Chen Chen, Wang Xia, Li Qiang, Zhao Yang, You Shoujiang, Ouyang Menglu, Robinson Thompson, Lindley Richard I, Arima Hisatomi, Chen Xiaoying, Chalmers John, Anderson Craig S, Song Lili
The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
Department of Stroke, The George Institute for Global Health China, Beijing, China.
Front Endocrinol (Lausanne). 2024 Dec 9;15:1341902. doi: 10.3389/fendo.2024.1341902. eCollection 2024.
The effect of renal impairment in patients who receive intravenous thrombolysis for acute ischemic stroke (AIS) is unclear. We aimed to determine the associations of renal impairment and clinical outcomes and any modification of the effect of intensive versus guideline-recommended blood pressure (BP) control in the BP arm of the International Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED).
We conducted a analysis of the ENCHANTED BP arm, which involved 2,196 thrombolyzed AIS patients. Logistic regression models were used to define the association between eGFR and clinical outcomes of death, death or major disability [modified Rankin scale (mRS) scores 3-6], and major disability (mRS 3-5) at 90 days.
Of the 2,151 patients with available baseline renal function data (mean age 66.9 years; 38% women), 993 (46.2%), 822 (38.2%), and 336 (15.6%) had normal (eGFR ≥ 90 mL/min/1.73 m), mildly (60-89), and moderate-to-severely impaired (<60) renal function, respectively. Compared with patients with normal eGFR, mortality was higher in those with moderate-to-severe renal impairment (adjusted odds ratio 1.77, 95% confidence interval 1.05-2.99; = 0.031 for trend). However, the difference in death or major disability (mRS 3-6) was not significant between groups. There was no heterogeneity in the effect of intensive versus guideline-recommended BP-lowering treatment on death by grades of renal function ( for interaction = 0.545).
The presence of moderate-to-severe renal impairment is associated with increased mortality in thrombolyzed patients with AIS. Renal function does not modify the effect of early intensive BP-lowering treatment on death in this patient group.
急性缺血性卒中(AIS)患者接受静脉溶栓治疗时肾功能损害的影响尚不清楚。我们旨在确定肾功能损害与临床结局之间的关联,以及在国际高血压强化控制与溶栓卒中研究(ENCHANTED)的血压组中,强化血压控制与指南推荐血压控制对疗效的任何改变。
我们对ENCHANTED血压组进行了分析,该组涉及2196例接受溶栓治疗的AIS患者。采用逻辑回归模型确定估算肾小球滤过率(eGFR)与90天时死亡、死亡或严重残疾(改良Rankin量表[mRS]评分3 - 6)以及严重残疾(mRS 3 - 5)等临床结局之间的关联。
在2151例有可用基线肾功能数据的患者中(平均年龄66.9岁;38%为女性),分别有993例(46.2%)、822例(38.2%)和336例(15.6%)肾功能正常(eGFR≥90 mL/min/1.73 m²)、轻度受损(60 - 89)和中度至重度受损(<60)。与eGFR正常的患者相比,中度至重度肾功能损害患者的死亡率更高(校正比值比1.77,95%置信区间1.05 - 2.99;趋势P = 0.031)。然而,两组之间死亡或严重残疾(mRS 3 - 6)的差异并不显著。强化降压治疗与指南推荐降压治疗对不同肾功能分级患者死亡的影响不存在异质性(交互作用P = 0.545)。
中度至重度肾功能损害与接受溶栓治疗的AIS患者死亡率增加有关。肾功能不会改变该患者群体早期强化降压治疗对死亡的影响。